NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I think the next most efficient comparison would be:

1. DCVax-l + poly-iclc + plx-3397
Versus
2. DCVax-l + poly-iclc + plx-3397+ CI
Versus
Control of:
3. DCVax-l + poly-iclc

You can see the cost of option 2 would be economically challenging, and also increase side effect potential, so I’m personally hoping option 1 proves its worth or option 3 holds its ground, although it could be all three options will be indication and/or patient specific. Just my humble opinion.

It’s possible the fourth option of:
4: DCVax-l + poly-iclc + CI

Will also still be in the running.

Imho, unless CI dosage can be greatly reduced, I see side effect and cost remaining a considerable challenge.